Greylin Investment Mangement Inc. boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 36.9% during the second quarter, Holdings Channel reports. The fund owned 294,495 shares of the company’s stock after buying an additional 79,300 shares during the period. Teva Pharmaceutical Industries Limited comprises 2.3% of Greylin Investment Mangement Inc.’s portfolio, making the stock its 11th largest position. Greylin Investment Mangement Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $9,783,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. Cribstone Capital Management LLC raised its position in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the last quarter. FNY Managed Accounts LLC purchased a new position in Teva Pharmaceutical Industries Limited during the first quarter valued at $123,000. Sterling Investment Advisors Ltd. raised its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the last quarter. Finally, Financial Architects Inc raised its position in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares during the last quarter. 56.19% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.7018% during midday trading on Wednesday, reaching $32.9899. 1,940,429 shares of the company traded hands. The firm has a 50-day moving average price of $31.54 and a 200-day moving average price of $32.37. The firm has a market capitalization of $33.52 billion, a price-to-earnings ratio of 422.9474 and a beta of 0.47. Teva Pharmaceutical Industries Limited has a one year low of $27.60 and a one year high of $55.79.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.06. The business had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The company’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.20 EPS. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Raised by Greylin Investment Mangement Inc.” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/07/26/teva-pharmaceutical-industries-limited-nyseteva-stake-raised-by-greylin-investment-mangement-inc.html.
TEVA has been the topic of several recent analyst reports. CIBC reissued a “buy” rating and set a $43.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, April 7th. Oppenheimer Holdings, Inc. set a $43.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research note on Thursday, April 6th. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $36.17 price objective on the stock. in a research note on Thursday, April 6th. Citigroup Inc. reduced their price objective on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Finally, Deutsche Bank AG reduced their price objective on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 12th. Fifteen investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $42.88.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
